Regulation of Food Preference Using GLP-1 Agonists

• US 20100222277A1
• Filed: 05/12/2010
• Published: 09/02/2010
• Est. Priority Date: 12/09/2003
• Status: Active Grant

• Current Assignee: Novo Nordisk A/S
• Original Assignee: Novo Nordisk A/S
• Inventors: MALMLÖF, KJELL, VON VOSS, PIA, RAUN, KIRSTEN, KNUDSEN, LISELOTTE BJERRE
• Granted Patent: US 9,486,504 B2
• Time in Patent Office: Days
• US Class Current: 514/1.100
• CPC Class Codes: A61K 38/2278 Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61P 1/14 Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/08 for glucose homeostasis pancreatic hormones A61P5/48
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

GLP-1 agonists selectively decrease the amount of food intake, wherein the food has a high glycemic index or wherein the amount of mono- and di-saccharides together constitute a large proportion of the total amount of carbohydrates.

Claims

1. A method for reducing intake of food having a glycemic index above 60% by a subject, said method comprising administering to said subject an effective amount of a GLP-1 agonist, wherein the subject to be treated has an increased appetite or craving for said food prior to the administration of said GLP-1 agonist and wherein after administration of said GLP-1 agonist said reduction in the intake of food with a glycemic index above 60% is accompanied by an increase in the intake of food with a low glycemic index, and wherein more than 30% of the total energy in said food having a glycemic index above 60% stems from fat.

4. A method according to claim 1, wherein said GLP-1 agonist is administered in connection with a meal.

5. A method according to claim 1, wherein said subject is a human, a pet animal or a zoo animal.

6. A method according to claim 5, wherein said subject is a human.

7. The method according to claim 1, wherein said GLP-1 agonist is a GLP-1(7-36)-amide or GLP-1(7-37).

8. The method according to claim 1, wherein said GLP-1 agonist is an analogue or a derivative of an analogue of GLP-1(7-36)-amide or GLP-1(7-37).

9. The method according to claim 8, wherein said derivative is Arg³⁴, Lys²⁶(N^ε

-(γ

-Glu(N^ε

-hexadecanoyl)))-GLP-1(7-37).

10. The method according to claim 1, wherein said GLP-1 agonist is exendin-4, an exendin-4 analogue or a derivative of said exendin-4 or exendin-4 analogue.

11. The method according to claim 10, wherein said GLP-1 agonist is exendin-4.

2. A method for reducing intake of food by a subject, wherein mono- and di-saccharides in said food together constitute more than 25% of the total amount of carbohydrate in said food and wherein more than 30% of the total energy in said food stems from fat, said method comprising administering to said subject an effective amount of a GLP-1 agonist, wherein the subject to be treated has an increased appetite or craving for said food prior to the administration of said GLP-1 agonist and wherein after administration of said GLP-1 agonist said reduction in the intake of said food is accompanied by an increase in the intake of food in which mono- and di-saccharides constitute less than 25% of the total amount of carbohydrate.

3. A method for treating a disease or disorder associated with an abnormal or excessive intake of food in a subject, the method comprising administering to said subject an amount of a GLP-1 agonist effective to treat said disease or disorder, wherein the subject to be treated has an increased appetite or craving for said food prior to the administration of said GLP-1 agonist and wherein after administration of said GLP-1 agonist the intake of food is reduced compared to a similar group not being administered a GLP-1 agonist, and wherein more than 30% of the total energy in said food stems from fat.

12. The method of claim 3, wherein the disease or disorder is selected from the group consisting of binge eating, bulimia nervosa and craving for food or snacking.

13. The method of claim 3, wherein the disease or disorder is obesity.